A Novel Transcriptional Score Predicting the Benefit of Anti-EGFR Antibodies for RAS Wild-Type Metastatic Colorectal Cancer: An In Silico Study

There is still an urgent need for precise biomarkers for predicting the clinical outcome of anti-EGFR antibody treatment for metastatic colorectal cancer. We hypothesized that transcriptome signatures might act as a more effective biomarker beyond RAS mutations and anatomic sites. This study was undertaken to develop a transcriptional score predictive of benefit of anti-EGFR antibodies for RAS wild-type metastatic colorectal cancer.